U.S. markets close in 4 hours 40 minutes
  • S&P 500

    3,738.39
    -52.54 (-1.39%)
     
  • Dow 30

    29,995.83
    -320.49 (-1.06%)
     
  • Nasdaq

    10,959.88
    -216.52 (-1.94%)
     
  • Russell 2000

    1,737.47
    -38.30 (-2.16%)
     
  • Crude Oil

    87.69
    +1.17 (+1.35%)
     
  • Gold

    1,718.00
    -12.50 (-0.72%)
     
  • Silver

    20.31
    -0.79 (-3.74%)
     
  • EUR/USD

    0.9863
    -0.0123 (-1.23%)
     
  • 10-Yr Bond

    3.7790
    +0.1620 (+4.48%)
     
  • GBP/USD

    1.1244
    -0.0231 (-2.01%)
     
  • USD/JPY

    144.7830
    +0.5840 (+0.40%)
     
  • BTC-USD

    19,911.58
    -196.53 (-0.98%)
     
  • CMC Crypto 200

    450.67
    -7.74 (-1.69%)
     
  • FTSE 100

    7,035.15
    -51.31 (-0.72%)
     
  • Nikkei 225

    27,120.53
    +128.32 (+0.48%)
     

News Flash: 12 Analysts Think Cerence Inc. (NASDAQ:CRNC) Earnings Are Under Threat

·3 min read

One thing we could say about the analysts on Cerence Inc. (NASDAQ:CRNC) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business.

Following this downgrade, Cerence's twelve analysts are forecasting 2023 revenues to be US$374m, approximately in line with the last 12 months. Statutory earnings per share are supposed to nosedive 98% to US$0.02 in the same period. Before this latest update, the analysts had been forecasting revenues of US$420m and earnings per share (EPS) of US$1.26 in 2023. It looks like analyst sentiment has declined substantially, with a substantial drop in revenue estimates and a pretty serious decline to earnings per share numbers as well.

Check out our latest analysis for Cerence

earnings-and-revenue-growth
earnings-and-revenue-growth

The consensus price target fell 14% to US$36.80, with the weaker earnings outlook clearly leading analyst valuation estimates. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Cerence at US$65.00 per share, while the most bearish prices it at US$27.00. As you can see the range of estimates is wide, with the lowest valuation coming in at less than half the most bullish estimate, suggesting there are some strongly diverging views on how think this business will perform. With this in mind, we wouldn't rely too heavily on the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Cerence's past performance and to peers in the same industry. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 0.3% by the end of 2023. This indicates a significant reduction from annual growth of 11% over the last three years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 13% per year. It's pretty clear that Cerence's revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The biggest issue in the new estimates is that analysts have reduced their earnings per share estimates, suggesting business headwinds lay ahead for Cerence. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. After such a stark change in sentiment from analysts, we'd understand if readers now felt a bit wary of Cerence.

Still, the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Cerence going out to 2024, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here